|1.||Chronic Obstructive Pulmonary Disease (COPD)
|1.||Mueller, Christian: 30 articles (11/2015 - 02/2004)|
|2.||O'Donnell, Denis E: 27 articles (06/2015 - 08/2002)|
|3.||Januzzi, James L: 24 articles (01/2016 - 12/2004)|
|4.||Bruera, Eduardo: 17 articles (12/2015 - 12/2003)|
|5.||Maisel, Alan S: 17 articles (04/2015 - 02/2002)|
|6.||Peacock, W Frank: 17 articles (04/2014 - 04/2004)|
|7.||Clopton, Paul: 17 articles (06/2013 - 01/2002)|
|8.||Maisel, Alan: 16 articles (11/2015 - 01/2002)|
|9.||Webb, Katherine A: 16 articles (06/2015 - 08/2002)|
|10.||Wu, Alan H B: 16 articles (06/2013 - 07/2002)|
12/01/2004 - "Dyspnea improved dramatically in the following 4 weeks and no more oxygen therapy was required. "
01/01/2011 - "Our patient had a dramatic and positive outcome: complete alleviation of dyspnea and oxygen dependence after PFO closure. "
02/01/2013 - "The domains and manifestations of HF, which were significantly improved by IMT in one or more of the 18 out of 19 studies of IMT, included dyspnea, quality of life, balance, peripheral muscle strength and blood flow, peripheral muscle sympathetic nervous activity, heart rate, respiratory rate, peak VO₂, 6-min walk test distance, ventilation, VE/VCO₂ slope, oxygen uptake efficiency, circulatory power, recovery oxygen kinetics and several indices of cardiac performance. "
01/01/2011 - "After the procedure the arterial oxygen pressure increased significantly in the upright position and dyspnea improved."
02/01/2010 - "Compared to T1 physical fitness (6-minute Walk Test, Hand-Force Test) as well as health-related quality of life (SF-36), dyspnea (BDI/TDI) and oxygen partial pressure (pO2) were significantly improved in T2. "
|2.||Brain Natriuretic Peptide (Natrecor)FDA Link
12/01/2011 - "Most recently, findings from the ASCEND-HF trial showed that nesiritide was safe with no adverse effects on renal function or mortality and was associated with a modest improvement in dyspnea. "
04/17/2012 - "Nesiritide had a greater effect than placebo on PEFR, and this predicted patients with moderate/marked improvement in dyspnea, thereby providing an objective metric for assessing AHF. "
02/01/2009 - "Prior studies have shown that dyspnea is improved in patients with ADHF 3 hours after nesiritide infusion with significant dose-related reductions in cardiac filling pressures and systemic vascular resistance without significant arrhythmias. "
02/12/2004 - "Used in conjunction with other clinical information, rapid measurement of B-type natriuretic peptide in the emergency department improved the evaluation and treatment of patients with acute dyspnea and thereby reduced the time to discharge and the total cost of treatment."
07/07/2011 - "Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P=0.03) and 24 hours (68.2% vs. 66.1%, P=0.007), but the prespecified level for significance (P≤0.005 for both assessments or P≤0.0025 for either) was not met. "
|3.||tiotropium (Spiriva)FDA Link
10/01/2010 - "Aclidinium and tiotropium also significantly increased FEV(1) (p < 0.01) and improved the perception of dyspnea compared with placebo at all measured time points from 10 minutes to 3 hours post-dose. "
03/01/2010 - "The use of tiotropium in isolation resulted in significant improvement in dyspnea at baseline (mean Medical Research Council scale score reduced from 3.0 to 2.5) and at the end of 6MWT (mean Borg scale score reduced from 6.1 to 4.5), and the differences were significant (p < 0.05 for both). "
12/01/2008 - "Tiotropium also provides superior bronchodilation and improvement in dyspnea at all time points, although onset of bronchodilation is slower than with long-acting beta(2)-agonists. "
12/01/2004 - "Clinically relevant outcomes such as the relief of dyspnea, improvement in the quality of life (health status), and reductions in the frequency and severity of acute exacerbations have been consistently obtained with tiotropium in clinical trials. "
01/01/2006 - "Tiotropium in combination with pulmonary rehabilitation produces clinically improvement in dyspnea, health status endurance of constant work compared to pulmonary rehabilitation alone. "
|4.||Opioid Analgesics (Opioids)IBA
05/01/2013 - "Consistent with existing evidence, most patients with dyspnea received opioids but only the combination of opioids and BZDs was independently associated with improvement in dyspnea. "
12/01/2014 - "The opioids used for treating dyspnea do not significantly compromise respiratory function; they are safe and effective."
03/01/2010 - "One review of randomized controlled trials and another randomized controlled trial found opioids effective in relieving dyspnea without causing major adverse effects. "
06/01/2010 - "The 'dyspnea target' and 'opioid responsiveness score' are proposed as a means of defining more clearly the sensations encountered by a given patient and the likelihood of symptomatic improvement in response to opioids. "
05/01/2015 - "Opioids are an effective treatment for dyspnea. "
|5.||Albuterol (Salbutamol)FDA LinkGeneric
05/01/2007 - "The second period of treatment elicited a significant further improvement in lung function and reduction in dyspnea score and salbutamol use in both groups. "
05/01/2007 - "The combination therapy with formoterol+tiotropium induced a significant improvement in mean predose FEV(1) and FVC at the end of the first period, and a significant reduction in dyspnea score as measure by a visual analogic scale and in use of rescue salbutamol. "
09/01/1991 - "Results showed a significant improvement of the daily number dyspnea episodes (from 2.7 to 1.4) and of the daily number of salbutamol puffs used as rescue medication (from 5,1 to 2,5) (p less than 0.001). "
10/15/2008 - "Inhalation of albuterol proved effective in reducing the dyspnea. "
12/01/2002 - "Separate studies have shown that inhaled albuterol, both a single dose (300 microg) and 2 weeks of therapy (200 microg/4x/day), reduces dyspnea. "
|6.||sildenafil (Viagra)FDA Link
01/01/2014 - "Sildenafil 50 mg/day resulted in a remarkable improvement of the dyspnea and Raynauds' with a significant improvement of the skin tightness as the MRSS became 22. "
04/01/2013 - "All patients exhibited improved exercise capacity with an increase of 6MWD from 63 to 268 (average 138.4±40.7) meters, significantly reduced Borg dyspnea score from maximum 9 down to 1 or 0, and reduced WHO functional class of PH from III or IV down to II. These results indicate that STS exhibits remarkable beneficiary effects on treating PH patients either alone or in concert with sildenafil."
07/01/2014 - "J receptor threshold doses were elevated in ES patients and fell significantly with sildenafil therapy that was associated with improved exercise tolerance, implying thereby a role of J receptors in producing dyspnea in ES patients."
12/01/2008 - "As compared to placebo sildenafil showed a significant improvement in 6-min walk test (68.90 (95% CI 31.14 - 106.65), p = 0.0003), mean pulmonary artery pressure (-13.04 (95% CI - 25.94 to -0.15), p = 0.05), mean cardiac index (0.39 (95% CI 0.24 - 0.54), p < 0.00001), mean Borg dyspnea score (-1.23 (95% CI -1.36 to -1.10), p < 0.00001), mean pulmonary vascular resistance (-171 (95% CI -300 to -30.90), p = 0.02), improvement in functional class (6.48 (95% CI 2.74 - 15.33), p < 0.001) and a nonsignificant change in mean right atrial pressure and clinical worsening. "
03/10/2005 - "NYHA class (baseline 3.8 +/- 0.4 vs. 4 weeks 2.4 +/- 0.5, p = 0.002), Borg dyspnea index (8.1 +/- 1.7 vs. 4.4 +/- 1.9, p = 0.0007), 6-min walk distance (234 +/- 44 vs. 377 +/- 128 m, p = 0.001) and Pulmonary artery pressure (125 +/- 15 vs. 113 +/- 18 mm Hg p = 0.05) are significantly improved with sildenafil 50 mg bid at 4 weeks. "
|7.||Morphine (MS Contin)FDA LinkGeneric
05/10/2008 - "The administration of subcutaneous morphine resulted in a significant reduction in dyspnea Visual Analog Scale (VAS) compared with placebo. "
05/01/2015 - "Morphine is the only opioid which has been clearly demonstrated as effective in the treatment of dyspnea. "
06/01/2005 - "Nine studies have evaluated the efficacy of nebulized morphine in relieving dyspnea. "
06/15/2001 - "Dyspnea improved during the adaptation period on the ward in 59.4% of the whole population being treated with morphine and in 67.7% of the analyzed patients after discharge. "
12/01/1990 - "Nineteen of 20 patients (95%) reported improved dyspnea after morphine. "
|8.||Bronchodilator Agents (Bronchodilators)IBA
01/01/2013 - "Since discharge, the patient had only occasional shortness of breath, relieved by bronchodilators. "
07/01/2000 - "We hypothesized that this collapse might mask the effects of bronchodilators during forced expiration but not during forced inspiration, and that accordingly, the improvement in forced inspiration and not that in forced expiration with bronchodilator therapy would be related to changes in the perception of dyspnea. "
10/15/2005 - "In studies with long-acting bronchodilators, e.g., the anticholinergic agent tiotropiumbromide, a reduction of expiratory flow limitation, hyperinflation and dyspnea could be demonstrated. "
07/01/2003 - "Combination of the two bronchodilators used in this study appears to alleviate perception of dyspnea more than use of either agent alone."
07/01/2003 - "This study was designed to investigate the impact of the combination of two bronchodilators on perception of dyspnea in these patients. "
|9.||pro-brain natriuretic peptide (1-76)IBA
12/01/2010 - "Dyspnea patients with elevated NT-proBNP concentrations and no improvement in either NT-proBNP or QOL at 30-days are at high risk of mortality and HF hospitalization. "
06/19/2007 - "In a universal health coverage system mandating judicious use of healthcare resources, inclusion of NT-proBNP testing improves the management of patients presenting to emergency departments with dyspnea through improved diagnosis, cost savings, and improvement in selected outcomes."
09/01/2014 - "The aim of this study was to evaluate the association between NT-proBNP and the stages of renal dysfunction in a typical population attended to emergency department with acute dyspnea. "
06/01/2013 - "A total of 1,445 patients attending the emergency department with acute dyspnea had measurements taken of MR-proANP, BNP, and NT-proBNP values on enrollment to the BACH trial and were grouped according to presence or absence of AF and HF. "
01/01/2012 - "The aim of the present study was to relate NT-proBNP plasma levels to different stages of renal function assessed with different methods in older adult subjects admitted because of dyspnea. "
04/01/2015 - "This reduction of autoantibody correlated with reduction in WLL frequency, increase in diffusing capacity for carbon monoxide, and subjective improvement in dyspnea. "
02/01/2011 - "Dyspnea on exertion, reduction of carbon-monoxide diffusing capacity (D(LCO)) and ground-glass attenuation areas on CT were improved by smoking cessation alone, and she was discharged. "
10/01/2010 - "The patient with only 5 months of posttreatment followup experienced an improvement in diffusing capacity for carbon monoxide from 44% to 77% predicted, but no change in dyspnea. "
01/01/2010 - "In a group of 127 patients with cardiac dyspnea, there was no difference in terms of the number of patients showing positive results with CO or BNP as judging criteria (122 vs 119, P = 0.393) and CO and BNP had negative correlation; while the results were opposite in a group of 227 patients with non-cardiac dyspnea (102 vs 11, showing negative CO or BNP P = 0.000) and there was no correlation between BNP and CO. "
01/01/2009 - "CO(2) respiration stimulates both anxiety and dyspnea ("air hunger") and has long been used to study panic vulnerability and respiratory control. "
11/01/2012 - "At the same time, the degree of dyspnea (1.3 ± 0.4) in the treatment group was significantly improved as compared with that (1.7 ± 0.4) in the control group after treatment. "
06/01/2011 - "The dyspnea indexes of both groups were significantly improved after treatment, but the improvement of group B was more significant than that of group A (u = -2.478, P < 0.05). "
01/01/2008 - "In this study, we aimed to compare the value of forced expiratory volume in the first second (FEV(1)) and inspiratory capacity (IC) measured before and after treatment in exacerbations and in the improvement in dyspnea. "
01/01/1941 - "The other three are much improved after treatment, as indicated by increase in vision and mental activity, loss of dyspnea, improvement in the electrocardiogram, etc. 8. The length of time the blood pressure remains lowered varies greatly in both animals and man. "
12/01/2015 - "No patient experienced dyspnea after treatment. "
|2.||Activities of Daily Living (ADL)
12/01/1994 - "After multiple bullectomy, this case showed marked improvements in lung function and gas exchange, subsequently his dyspnea improved, as did his activities of daily living. "
09/01/2009 - "In all five studies in which training load was adequately controlled, a significant reduction of dyspnea during activities of daily living was found. "
01/01/2013 - "Group A patients also showed significant: 1) improvement in the degree of dyspnea (VAS: p < 0.05; Borg: p < 0.05; MRC: p < 0.001; BDI1: p < 0.05; BDI3: p < 0.03), and independence level in activities of daily living (p < 0.03); 2) improvement in quality of life in activity section (- 6.63 pt) and in total score (- 5.43 pt); 3) exacerbation number decrease (p < 0.02). "
01/01/2009 - "The ulcerated lesions on the anterior chest, dyspnea, ADL and QOL improved significantly, without the development of any serious adverse effects. "
09/01/2005 - "Dyspnea with activities of daily living and self-reported physical functioning significantly improved for all groups over time. "
|3.||Drug Therapy (Chemotherapy)
02/01/2012 - "There was significant heterogeneity in quality-of-life scales used; compared with pharmacotherapy, AVNA was associated with significant improvement in several symptoms (palpitations, dyspnea). "
03/01/2005 - "The use of LTOT for hypoxemic patients has resulted in increased survival, and expanded drug therapy options have effectively improved dyspnea and quality of life. "
06/01/1999 - "His dyspnea improved following irradiation and corticosteroid treatment and one month later, he was admitted again for chemotherapy. "
06/01/2014 - "The findings in our study showed that patients, in spite of considerable difficulties with shortness of breath, found relief in several types of activities, in addition to drug therapy. "
01/01/2015 - "Shortness of breath was the main symptom, which was aggravated by chemotherapy in 28 (13%), and medical/surgical procedures in 21 (9%) and showed diurnal change in intensity in 32 (14%). "
03/01/2008 - "During the 4 to 7 month followup, after stent implantation, clinical signs, including dyspnea and respiratory distress, dramatically improved in all dogs. "
11/01/1995 - "All patients with malignant lesions improved symptomatically after stent placement and remained without significant dyspnea until death (from 1 to 6 months). "
12/01/2010 - "The HCPA-1 stent proved to be safe, with no severe complications during the study period, and effective in improving quality of life with relief of dyspnea."
07/01/2014 - "Dyspnea was relieved immediately after stent placement. "
03/01/2012 - "Of these 13 lesions, eight patients with dyspnea underwent re-interventions with metallic stent replacement and improved. "
|5.||Pneumonectomy (Lung Volume Reduction)
03/01/2010 - "Currently available data on efficacy of bronchoscopic lung volume reduction are not consistently conclusive, and subjective benefit in dyspnea scores is a more frequent finding than improvements on spirometry or exercise tolerance. "
08/01/1996 - "Lung volume reduction is a surgical procedure that is effective in relieving the dyspnea and improving the patient's quality of life."
01/01/2010 - "The currently available data on efficacy of bronchoscopic lung volume reduction are not conclusive, although subjective benefit in dyspnea scores and quality of life is a frequent finding. "
08/01/2009 - "The improvement in exercise capacity and dyspnea following lung volume reduction surgery is associated with a substantial reduction in neural drive to the inspiratory muscles."
12/01/2007 - "Two-year improvement in multidimensional body mass index, airflow obstruction, dyspnea, and exercise capacity index after nonresectional lung volume reduction surgery in awake patients."